True North Advisors’s Kyntra Bio KYNB Stock Holding History

True North Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-600	Closed	-$240K	–	202
2022 Q4	$240K	Buy	+600	New	+$230K	0.08%	153

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

True North Advisors's KYNB Position: Q1 2023 in Review

True North Advisors sold out of Kyntra Bio (KYNB) in Q1 2023, closing a stake of 600 shares — an estimated $240K sold.

True North Advisors first reported a position in KYNB in Q4 2022 and held it in 1 quarter. The position peaked at $240K in Q4 2022. 171 funds tracked by Wall St. Rank hold KYNB as of Q1 2023.

True North Advisors reported no remaining Kyntra Bio position as of Q1 2023 after selling out during the quarter.
True North Advisors sold 600 Kyntra Bio shares in Q1 2023, an estimated $240K.
True North Advisors first reported a position in Kyntra Bio in Q4 2022 and held it in 1 quarter.
True North Advisors's Kyntra Bio position peaked at $240K in Q4 2022.
171 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2023.

Based on True North Advisors's 13F filing for Q1 2023, filed 15 May 2023.